This trial is testing whether two immunotherapy drugs can help shrink tumors in patients with liver cancer that has spread.
- Stage IVB Hepatocellular Carcinoma
- Hepatocellular Carcinoma (HCC)
- Liver Cancer
- Stage III Liver Cancer
- Stage IIIA Hepatocellular Carcinoma
- Stage IIIB Hepatocellular Carcinoma
- Stage IV Liver Cancer
- Stage IVA Hepatocellular Carcinoma
- Unresectable Liver Cancer
1 Primary · 4 Secondary · Reporting Duration: Up to 2 years
Side Effects for
1 Treatment Group
Treatment (nivolumab, ipilimumab)
1 of 1
40 Total Participants · 1 Treatment Group
Primary Treatment: Nivolumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 19 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the FDA sanctioned Nivolumab for clinical use?
"Our team at Power has assigned nivolumab a score of 2 on the safety scale, due to the data collected during Phase 2 clinical trials that confirm its relative security but lack evidence for efficacy." - Anonymous Online Contributor
Is enrollment open for this research endeavor?
"Unfortunately, the trial listing on clinicaltrials.gov reveals that this medical study is no longer accepting participants; it was posted on November 30th of 2022 and last updated September 23rd. Nonetheless, there are still 2598 other trials beckoning for recruits at present time." - Anonymous Online Contributor
What is the geographic scope of this trial's management?
"There are 6 sites across the nation that currently have open slots for this medical trial. Examples include Emory University Hospital/Winship Cancer Institute in Atlanta, University of Miami Miller Schoolof Medicine-Sylvester Cancer Center in Miami, and Rutgers Cancer Institute of New Jersey in New Brunswick." - Anonymous Online Contributor